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Fibrinogen is a hexameric protein composed of Aa, Bb
and g chain pairs [1] encoded by three paralogous genes,
FGA, FGB and FGG [2]. Fibrinogen variants are the
consequence of mutations in FGA, FGB or FGG and
may result in afibrinogenaemia, hypofibrinogenaemia,
dysfibrinogenaemia or hypodysfibrinogenaemia. Dysfi-
brinogenaemia is characterized by a fibrinogen structural
abnormality responsible for altered functional properties
[3]. The majority of the mutations are located in FGA,
followed by FGG and the fewest in FGB8 [4]. Mutations
in FGB are functionally interesting because Bb chain
synthesis is thought to be rate-limiting for mature fibri-
nogen production [5]. The associated clinical symptoms
range from easy bruising, excessive bleeding (i.e. nose
and mucosal bleeds, genitourinary tract, gastrointestinal
tract and intracranial haemorrhage) to thromboembolic
events. A database for human fibrinogen variants is
available at http://www.geht.org.
Here we report a patient with dysfibrinogenaemia. This is
a 49-year-old Swiss female referred in September 2010 to
Lausanne University Hospital for investigation of a
bleeding disorder. She presented with a history of post-
partum bleeding after the vaginal delivery of her first
child in 1987 without blood transfusion. Her two follow-
ing children were born by vaginal delivery without com-
plication. In 2006, she experienced massive bleeding
requiring blood transfusions after a hysterectomy for a
fibromyoma and in 2010 local bleeding after a fine needle
aspiration to investigate a breast lump for which no blood
transfusion was required. The patient complained about
menorrhagia until hysterectomy and required iron repla-
cement therapy for iron deficiency anaemia. Tooth
extractions were performed without excessive bleeding.
She did not have epistaxis, easy bruising, spontaneous
haematomas or gastrointestinal bleeding. As in Shapiro
et al. publication [6], we used the International Society
on Thrombosis and Hemostasis concensus bleeding
assessment tool, and her score was 2. She had no history
of thrombosis or miscarriage. Her family history was
uneventful with the exception of her daughter who
suffers from menorrhagia.
Blood count and morphology, activated partial thrombo-
plastin, prothrombin and thrombin times, factor VIII, von
Willebrand factor antigen and activity and factor XIII
were normal. Platelet Function Analyzer-100 (PFA-100)
closure time (collagen/ADP and collagen/epinephrine
cartridges) was within the normal range. Platelet aggre-
gation measurement was not performed.
Functional fibrinogen level (Clauss method) was
decreased to 1.4 g/l (N¼ 2.0–4.0). Immunoreactive fibri-
nogen level was 2.3 g/l (N¼ 1.5–3.5), implying a qualita-
tive defect of fibrinogen. Family screening showed that
her daughter had a functional fibrinogen level of 2.4 g/l.
Her two sons were asymptomatic and refused further
investigations.
After obtaining patient-informed consent, blood was
collected for genetic analysis by amplification and
sequencing of all the coding sequences and the splicing
sites of the FGA, FGB and FGG genes. We identified a
novel heterozygous deletion in FGB exon 4: c.680delG.
This single base-pair deletion leads to a frame shift and is
predicted to produce an aberrant fibrinogen beta-chain
with 45 abnormal residues (starting with Cys227Ser,
numbered from the initiator Met) before a premature
in-frame stop codon TGA. Such a severe truncating
mutation, eliminating the entire beta-chain C-terminal
globular domain, which is important for fibrinogen
secretion [7], may intuitively be thought more likely to
be associated with a quantitative rather than a qualitative
defect. However, beta-chains deleted from residue
238, which have an intact coiled-coil domain (residues
157–222), have previously been shown to be assembled
and secreted [8]. It is therefore likely that the aberrant
beta-chain produced as a consequence of c.608delG,
which also preserves an intact coiled-coil, is present in
the patient’s circulation in the form of abnormal hexam-
ers, which impair normal fibrin clot formation, thus caus-
ing the observed bleeding symptoms.
In the database for human fibrinogen variants (http://
www.geht.org), version 37, updated January 2012), 84
FGB variants (59 distinct mutations) are reported
accounting for 39 dysfibrinogenaemic (d), 21 afibrinogen-
aemic (a), 22 hypofibrinogenaemic (h) and two hypodys-
fibrinogenaemic cases (hd). Thirty-two cases presented
with haemorrhage (10d, 9a, 11 h, 2hd), 15 with thrombosis
(14d, 1a), six with both complications (4a, 2 h), 15 were
reported asymptomatic (10d, 5 h) and for 15 cases clinical
data were missing (4d, 7a, 4 h). To our knowledge, there
is only one case reported with a variant affecting the same
amino acid residue as our patient [9]. This is an afibri-
nogenaemic patient homozygous for a missense mutation
(FGB c.680 G>T, Cys227Phe) who showed spontaneous
intracerebral bleeding. Cys227 is located in the conserved
fibrinogen beta globular C-ter domain and is involved in
the formation of a disulfide bridge with Cys161 in the
gamma-chain. In this case, the complete fibrinogen
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deficiency can be explained by an abnormal three-dimen-
sional structure of the beta-chain C-ter domain, which
does not allow hexamer assembly and secretion as pre-
viously mentioned [7].
Our patient, a heterozygous carrier of 680delG with
dysfibrinogenaemia, had an abnormal bleeding score.
Her first bleeding event was a postpartum haemorrhage
after a difficult vaginal delivery, a situation also occurring
in normal subjects. Moreover, it is worth noticing that her
two following vaginal deliveries were not complicated by
bleeding. Referring to the literature [10], women with
dysfibrinogenaemia and a history of recurrent poor preg-
nancy outcome were treated with prophylactic fibrinogen
concentrate infusions as soon as pregnancy was confirmed
using a target trough fibrinogen level of 1 g/l. In afibrino-
genaemic/hypofibrinogenaemic patients, fibrinogen
levels are maintained over 1 g/l during pregnancy and
for delivery. According to these guidelines, our patient
would not have received a prophylactic substitution
during her first pregnancy and delivery. Indeed, her
baseline level was above 1 g/l, so no further measures
would have been undertaken. Knowing the diagnosis,
when the postpartum haemorrhage occurred, a substi-
tution might have achieved an earlier haemostatic effi-
cacy and thereby a reduced overall bleeding.
Both bleeding after hysterectomy and local bleeding
after a fine needle aspiration in a breast lump can be
considered standard complications after such pro-
cedures.
According to the UK guidelines [11], patients with dysfi-
brinogenaemia with a bleeding phenotype should be
treated with fibrinogen concentrate preoperatively to
raise and maintain the fibrinogen level to 1 g/l above
their baseline level until haemostasis is secure and
0.5 g/l until wound healing is complete. Knowing the
diagnosis, our patient would have been prophylactically
substituted, which could have prevented the bleeding.
In conclusion, we have identified a novel heterozygous
frame shift mutation in FGB exon 4: c.680delG. This
mutation is associated with dysfibrinogenaemia and a
mild history of bleeding but no thrombosis.
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The recent report on ‘coagulation profile in patients with
H1N1 influenza A infection undergoing treatment for
haematological malignancies’ is very interesting [1].
Rupa-Matysek et al. [1] observed that ‘the association
between coagulation activation and poor outcome
pH1N1 infection was found in the analyzed group’. In
fact, the coagulation disorder in the patient with H1N1
influenza A infection is an interesting topic. This problem
can be seen in both typical and atypical H1N1 influenza A
infection [2]. In the present report, the problem in the
patient with H1N1 influenza A infection is possible.
However, an important concern is the concomitant hem-
atological malignancies. The remaining question is how
we can assure that the coagulation is the result of H1N1
influenza infection, hematological malignancies or com-
bination of both disorders. For sure, the problem is of
concern for the hematologist. Some leukemic patients
infected with H1N1 influenza virus can further develop
serious complications such as hemophagocytic lympho-
histiocytosis that can be fatal [3]. The coagulation dis-
order is an important presentation of such complications
[3].
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